Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2017-2018 Formulations

NCT03308825 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.

NCT NCT03308825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03308825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2017-2018 Formulations
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Phase
Phase 4
Overall status
Completed
Start date
September 11, 2017
Completion date
November 22, 2017
Enrollment
240 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

flu, influenza